Business Wire

Recursion Releases Open-Source Data from Largest Ever Dataset of Biological Images, Inviting Data Science Community to Develop New and Improved Machine Learning Algorithms for ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a Fast Company “Most Innovative Company” and leader in the artificial intelligence for drug discovery movement, today announced it will open-source a ...
PharmiWeb

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient ...
GEN

As Pipeline Advances, Recursion Expands AI Focus to Clinical Trials

Najat Khan, PhD, Recursion Pharmaceuticals chief R&D officer and chief commercial officer With at least seven of its programs expected to begin human trials or read out clinical data during 2025, ...
Nature

Creating an AI-first drug discovery engine

When Recursion launched in 2013, the fledgling biotech’s goal was to turn machine vision loose on images of cells, at scale, to better understand the biology of disease. Exscientia, founded the year ...
GEN

Roche, Genentech, Recursion Launch Up-to-$12B AI Drug Discovery Effort

Recursion co-founder & CEO Chris Gibson, PhD Roche and its Genentech subsidiary have committed up to $12 billion to Recursion in return for using its Recursion Operating System (OS) to advance ...
C&EN

MIT and Recursion partner for AI drug discovery tool

The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. “Affinity was an open problem for decades,” Barzilay ...